Table 5. Response to treatment.

	Week 25		Entire study period
	Nivolumab followed by ipilimumab (n=68)	Ipilimumab followed by nivolumab (n=70)	Nivolumab followed by ipilimumab (n=68)	Ipilimumab followed by nivolumab (n=70)
Best overall response
Complete response	··	··	8/68 (12%)	4/70 (6%)
Partial response	··	··	30/68 (44%)	18/70 (26%)
Stable disease	··	··	2/68 (3%)	6/70 (9%)
Progressive disease	··	··	15/68 (22%)	20/70 (29%)
Unable to determine	··	··	13/68 (19%)	22/70 (31%)
Overall response, n/N (%; 95% CI)	28/68 14/70 (41%; 29·4-53·8)*	(20%; 11·4-31·3)*	38/68 (56%; 43·3-67·0)	22/70 (31%; 20·9-43·6)
Median duration of overall response, months (IQR)	··	··	NR (8·4-19·3)	NR (7·5-17·2)
Overall response by PD-L1 expression, n/N evaluable (%; 95% CI)
PD-L1 <5%	8/31 (26%; 11·9–44·6)	3/34 (9%; 1·9-237)	13/31 (42%; 24·5-60·9)	6/34 (18%; 6·8-34·5)
PD-L1 ≥5%	12/22 (55%; 32·2-75·6)	4/10 (40%; 12·2-73·8)	16/22 (73%; 49·8-89·3)	6/10 (60%; 26·2-87·8)

Data are n/N (%) unless otherwise indicated. NR=not reached. PD-L1=programmed death ligand 1. The assessment of best overall response disregarded the week 13 tumour assessment. Reasons for patients judged as “unable to determine” include discontinuation, start of a subsequent anticancer therapy, or death before the week 25 assessment; and no evaluable tumour assessment done beyond the week 13 timepoint.

^*Confirmed with scan at week 33 (or any subsequent scan done ≥4 weeks after the week 25 scan).